Shares of Allarity Therapeutics, Inc. (ALLR) are surging more than 125% Tuesday morning at $2.69.
Monday, the company said it initiated the Phase 1b study of the combination therapy of its drug candidates stenoparib and dovitinib to treat advanced solid tumors, including ovarian cancer.
Interim data readouts from the ongoing Phase 2 monotherapy studies of Dovinitinb and Stenoparib are expected in late 2023.
ALLR has traded in the range of $1.04- $118.30 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.